Study Details

General Information

Sanofi EFC14867

A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study Evaluate the Efficacy and Safety of Sotagliflozin compared to Empagliflozin, and Placebo in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin.

ProtocolEFC14867
IdentifierSite Number: 8408020
UIDdec2e356-1235-4d58-8c50-6af682ae6fe3
StatusCancelled
Phase3
CategoryDiabetes Type 2 / Adult
Launch Year2017
NCT Number-
Created2017-08-11 13:12
Last Updated2017-08-11 13:12

Description

No description provided.

Comment

No comment.

Target Dates

NameDateRequired
Enrollment ClosedNo
Enrollment OpenNo
First Patient First VisitNo
Site Initiation Mtg.No
PI Meeting StartNo
PI Meeting EndNo
PI Meeting ArrivalNo
PI Meeting DepartureNo
Closeout DateNo
Final PatientVisitNo
PreStudy Selection VisitNo
Target Date 12No
Target Date 13No
Target Date 14No

Leadership

RoleStaffLoginRequired
PrincipalMartinez, GilbertGJMartinezNo
RecruiterMiss, SalomonSMissNo
CoordinatorValenzuela, LouisitoLValenzuelaNo
RegulatoryPerez, MyrnaMPerezNo

Custom Fields

No custom fields.

Sponsor & Organization

SponsorSanofi-Aventis
DivisionSanofi-Aventis
TeamSanofi-Aventis
Managing SiteCatalina Research Institute, LLC
Organization

Contacts

IRB Ref
CROCovance -LabCorp Drug Development
CRO Ref
Correspondence0

Opportunity

Probability0
Comment
Status ColorYellow
Currency-
Mayra Sibley

2 Hours

Hi there, I'm Jesse and you?
You

3 minutes

My name is Anne Clarc.
Mayra Sibley

40 seconds

Nice to meet you Anne.
How can i help you?